Montedori A, Bonacini MI, Casazza G, et al. Modified versus standard intention-to-treat reporting: are there differences in methodological quality, sponsorship, and findings in randomized trials? A cross-sectional study. Trials. 2011;12:58.
Liu-seifert H, Zhang S, D'souza D, Skljarevski V. A closer look at the baseline-observation-carried-forward (BOCF). Patient Prefer Adherence. 2010;4:11-6.
Del Re AC, Maisel NC, Blodgett JC, Finney JW. Intention-to-treat analyses and missing data approaches in pharmacotherapy trials for alcohol use disorders. BMJ Open. 2013;3(11):e003464.
Beckett RD, Loeser KC, Bowman KR, Towne TG. Intention-to-treat and transparency of related practices in randomized, controlled trials of anti-infectives. BMC Med Res Methodol. 2016;16(1):106. (Definitions for ITT, mITT, and PP can be found in table 1).
Committee for Proprietary Medicinal Products (CPMP). Points to consider on switching between superiority and non-inferiority. British Journal of Clinical Pharmacology 2001;52(3):223-228. Article available in PubMed Central.
Wang B, Wang H, Tu XM, Feng C. Comparisons of Superiority, Non-inferiority, and Equivalence Trials. Shanghai Arch Psychiatry. 2017;29(6):385-388. doi:10.11919/j.issn.1002-0829.217163